{"id":"https://openalex.org/W2212833192","doi":"https://doi.org/10.1158/1538-7445.sabcs14-p2-15-04","title":"Abstract P2-15-04: A phase 1/2 study of Ad.p53 DC vaccine with indoximod immunotherapy in metastatic breast cancer","display_name":"Abstract P2-15-04: A phase 1/2 study of Ad.p53 DC vaccine with indoximod immunotherapy in metastatic breast cancer","publication_year":2015,"publication_date":"2015-05-01","ids":{"openalex":"https://openalex.org/W2212833192","doi":"https://doi.org/10.1158/1538-7445.sabcs14-p2-15-04","mag":"2212833192"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs14-p2-15-04","doi":"https://doi.org/10.1158/1538-7445.sabcs14-p2-15-04","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs14-p2-15-04","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090789911","display_name":"Hatem Hussein Soliman","orcid":"https://orcid.org/0000-0001-6644-2264","observed_orcids":["https://orcid.org/0000-0001-6644-2264"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hatem H Soliman","raw_affiliation_strings":["1Moffitt Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Moffitt Cancer Center","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111541235","display_name":"Susan E. Minton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan E Minton","raw_affiliation_strings":["1Moffitt Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Moffitt Cancer Center","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015970851","display_name":"Roohi R. Ismail-Khan","orcid":"https://orcid.org/0000-0002-1301-6736","observed_orcids":["https://orcid.org/0000-0002-1301-6736"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roohi Ismail-Khan","raw_affiliation_strings":["1Moffitt Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Moffitt Cancer Center","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059240684","display_name":"Hyo Sook Han","orcid":"https://orcid.org/0000-0002-0072-0257","observed_orcids":["https://orcid.org/0000-0002-0072-0257"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hyo S Han","raw_affiliation_strings":["1Moffitt Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Moffitt Cancer Center","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070688456","display_name":"Nicholas N. Vahanian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127016","display_name":"NewLink Genetics (United States)","ror":"https://ror.org/03spep839","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127016"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicholas N Vahanian","raw_affiliation_strings":["2NewLink Genetics Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2NewLink Genetics Inc","institution_ids":["https://openalex.org/I4210127016"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112243123","display_name":"Charles J. Link","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127016","display_name":"NewLink Genetics (United States)","ror":"https://ror.org/03spep839","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127016"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles J Link","raw_affiliation_strings":["2NewLink Genetics Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2NewLink Genetics Inc","institution_ids":["https://openalex.org/I4210127016"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042047369","display_name":"G Kennedy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127016","display_name":"NewLink Genetics (United States)","ror":"https://ror.org/03spep839","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127016"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gene Kennedy","raw_affiliation_strings":["2NewLink Genetics Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2NewLink Genetics Inc","institution_ids":["https://openalex.org/I4210127016"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090809833","display_name":"HOWARD Z. STREICHER","orcid":"https://orcid.org/0000-0003-3683-9804","observed_orcids":["https://orcid.org/0000-0003-3683-9804"]},"institutions":[{"id":"https://openalex.org/I4210123359","display_name":"National Cancer Institute","ror":"https://ror.org/02t771148","country_code":"UA","type":"facility","lineage":["https://openalex.org/I4210123359"]}],"countries":["UA"],"is_corresponding":false,"raw_author_name":"Howard Streicher","raw_affiliation_strings":["3National Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3National Cancer Institute","institution_ids":["https://openalex.org/I4210123359"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102841436","display_name":"Daniel M. Sullivan","orcid":"https://orcid.org/0009-0003-0951-9781","observed_orcids":["https://orcid.org/0009-0003-0951-9781","https://orcid.org/0000-0002-2183-1773"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Sullivan","raw_affiliation_strings":["1Moffitt Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Moffitt Cancer Center","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5046273815","display_name":"Scott Joseph Antonia","orcid":"https://orcid.org/0000-0002-6686-3824","observed_orcids":["https://orcid.org/0000-0002-6686-3824"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott J Antonia","raw_affiliation_strings":["1Moffitt Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Moffitt Cancer Center","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"75","issue":"9_Supplement","first_page":"P2","last_page":"15"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.9829000234603882,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.9829000234603882,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.009999999776482582,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/indoximod","display_name":"indoximod","score":0.9629999995231628},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.8389999866485596},{"id":"https://openalex.org/keywords/indoleamine-2-3-dioxygenase-inhibition","display_name":"indoleamine 2,3-dioxygenase inhibition","score":0.9110000133514404},{"id":"https://openalex.org/keywords/adoptive-immunotherapy","display_name":"adoptive immunotherapy","score":0.5649999976158142},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.8870000243186951},{"id":"https://openalex.org/keywords/vaccine-safety","display_name":"vaccine safety","score":0.5730000138282776},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.44699999690055847},{"id":"https://openalex.org/keywords/immunosuppressive-tumor-microenvironment","display_name":"immunosuppressive tumor microenvironment","score":0.7639999985694885},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.5370000004768372},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.6039999723434448},{"id":"https://openalex.org/keywords/adenovirus-vectored-vaccine","display_name":"adenovirus vector vaccine","score":0.4269999861717224}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7961691617965698},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5959353446960449},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5918580293655396},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.581673264503479},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.5790396928787231},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.562349259853363},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5185281038284302},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.502997100353241},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4977100193500519},{"id":"https://openalex.org/C2778170410","wikidata":"https://www.wikidata.org/wiki/Q506253","display_name":"Dendritic cell","level":3,"score":0.4801977872848511},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.33894026279449463},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.33458709716796875},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3124569058418274}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs14-p2-15-04","doi":"https://doi.org/10.1158/1538-7445.sabcs14-p2-15-04","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs14-p2-15-04","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.8500000238418579,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4255855348","https://openalex.org/W2601304651","https://openalex.org/W2783488707","https://openalex.org/W2395215198","https://openalex.org/W2598118864","https://openalex.org/W2094454810","https://openalex.org/W3013416722","https://openalex.org/W4298869405","https://openalex.org/W3095405058","https://openalex.org/W2328678748"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Indoleamine":[2],"2,3":[3],"dioxygenase":[4],"(IDO)":[5],"is":[6,18,36],"a":[7,52,145,190,437,494],"tryptophan-catabolizing":[8],"enzyme":[9],"that":[10],"causes":[11],"immunosuppression":[12],"in":[13,153,157,202,303,357,361,432,447,471,486,507,550],"the":[14,28,62,67,84,164,350,364,378,426,433,448,463,558],"tumor":[15],"microenvironment.":[16],"Indoximod":[17],"an":[19,37],"IDO":[20],"pathway":[21],"inhibitor.":[22],"Preclinical":[23],"data":[24,79,102],"suggests":[25],"indoximod":[26,57,130,548],"enhancs":[27],"activity":[29],"of":[30,56,66,170,200,240,260,327,337,384,389,420,425,443,476,497,543,557],"dendritic":[31,43],"cell":[32,44],"(DC)":[33,45],"vaccines.":[34],"Ad.p53":[35,138,544],"adenovirus":[38],"used":[39,144],"to":[40,60,72,121,136,184,246,296,301,466,483],"generate":[41],"autologous":[42],"vaccines":[46],"against":[47],"p53":[48,205],"epitopes.":[49],"We":[50],"initiated":[51],"phase":[53,76,99,108,126,226,304,352,358,362,379,461,540],"1/2a":[54],"trial":[55,143],"+":[58],"Ad.p53DC":[59],"explore":[61],"safety":[63,78],"and":[64,83,103,117,284,290,413],"efficacy":[65],"combination":[68],"along":[69],"with":[70,89,134,160,189,193,322,374,505,547],"response":[71,120,162,168,187,300,465],"subsequent":[73,119,484],"chemo.":[74,123,261],"The":[75,125,142,179],"1":[77,238,257,342,346,375,380,480],"were":[80,213,229,270,280,294],"previously":[81],"presented":[82],"treatment":[85,216,272,277,504],"was":[86,172,451,457,469],"well":[87,458],"tolerated":[88],"no":[90,210,271],"DLTs.":[91],"(Soliman,":[92],"ASCO":[93],"2013)":[94],"This":[95],"abstract":[96],"includes":[97],"new":[98],"2a":[100,127],"safety/efficacy":[101],"updated":[104],"outcomes":[105],"on":[106],"all":[107],"1/2":[109,353,462,541],"metastatic":[110,195,203,434,551],"breast":[111,196,354,552],"cancer":[112,553],"patients":[113,228,254,324,331,392,409],"who":[114,332],"received":[115,236,333],"Adp53DC+indoximod":[116],"any":[118,266],"salvage":[122],"Methods:":[124],"study":[128,180,542],"combined":[129],"1600mg":[131],"PO":[132],"BID":[133],"up":[135],"6":[137],"DC":[139,545],"vaccinations":[140],"q2wks.":[141],"single":[146],"arm,":[147],"Simon":[148],"two":[149],"stage":[150],"design":[151],"(n=12":[152],"1st":[154],"stage,":[155],"25":[156],"2nd":[158],"stage)":[159],"objective":[161],"as":[163,326,383],"primary":[165],"endpoint.":[166],"One":[167],"out":[169,388],"12":[171],"required":[173],"for":[174],"progression":[175,220,249],"into":[176],"second":[177],"stage.":[178],"had":[181,255,401,410,428],"90%":[182],"power":[183],"detect":[185],"20%":[186],"rate":[188],"p=.09.":[191],"Patients":[192],"measurable,":[194],"cancer,":[197],"<3":[198],"lines":[199,442],"chemo":[201,449],"setting,":[204],"IHC":[206],">5%,":[207],"ECOG":[208],"0-2,":[209],"autoimmune":[211],"disease":[212,219,248,297],"eligible.":[214],"Study":[215],"continued":[217],"until":[218],"or":[221],"unacceptably":[222],"toxicity.":[223],"Results:":[224],"Twelve":[225],"2":[227,234,310,335,397],"accrued,":[230],"9":[231,360],"(7":[232],"TNBC,":[233],"ER+/HER2-)":[235],"\u2265":[237,256,334],"dose":[239],"Ad.p53DC+indoximod":[241],"(3":[242],"did":[243,414],"not":[244,415],"due":[245,295],"rapid":[247,411],"during":[250],"vaccine":[251,546],"preparation).":[252],"Six":[253],"prior":[258,430,441],"line":[259],"Seven":[262],"(58%)":[263],"subjects":[264],"experienced":[265],"grade":[267],"AE,":[268],"there":[269],"related":[273],"AEs":[274,279],"\u2265G3.":[275],"All":[276,292,422],"attributable":[278],"G1-2,":[281],"<10%":[282],"frequency,":[283],"included":[285],"anemia,":[286],"nausea,":[287],"lymphopenia,":[288],"photophobia,":[289],"headache.":[291],"discontinuations":[293],"progression.":[298],"Best":[299],"immunotherapy":[302,340,407,467,549],"2=1":[305],"SD,":[306,398],"8":[307],"PD.":[308],"Phase":[309],"median":[311,365],"TTP":[312,366],"=":[313,318,367],"6.85":[314],"wks":[315,320,453],"(3.8-18.1),":[316],"OS":[317,446],"18.1":[319],"(3.8-52)":[321],"3":[323,344],"alive":[325,382],"June":[328,385],"2014.":[329,386],"Five":[330],"cycles":[336],"chemotherapy":[338,405,431,485,506],"after":[339,406,439],"demonstrated":[341],"PR,":[343,396],"PD,":[345],"pending":[347],"scan.":[348],"For":[349],"entire":[351],"cohort":[355,381],"(21":[356],"1,":[359],"2)":[363],"9.85":[368],"weeks":[369],"(3.8-22.1),":[370],"OS=38.7":[371],"(3.8-122.1)":[372],"weeks,":[373],"patient":[376],"from":[377,404],"Ten":[387],"21":[390,477],"evaluable":[391],"(1":[393],"CR,":[394],"7":[395],"11":[399],"PD)":[400],"clinical":[402],"benefit":[403],"(9":[408],"decline":[412],"get":[416],"one":[417,424],"full":[418],"cycle":[419],"therapy).":[421],"but":[423],"responders":[427,450],"seen":[429],"setting":[435],"(including":[436,479],"CR":[438],"4":[440,472],"chemo).":[444],"Median":[445],"69.4":[452],"(30.1-122.1).":[454],"Conclusions:":[455],"Indoximod+Ad.p53DC":[456],"tolerated.":[459],"Across":[460],"best":[464],"alone":[468],"SD":[470],"pts":[473],"while":[474],"10":[475],"(47%)":[478],"CR)":[481],"responded":[482],"this":[487,503],"largely":[488],"pretreated":[489],"cohort.":[490],"There":[491],"may":[492],"be":[493],"chemosensitization":[495],"effect":[496],"indoximod+Ad.p53DC.":[498],"Future":[499],"trials":[500],"should":[501],"combine":[502],"appropriately":[508],"selected":[509],"patients.":[510],"Citation":[511],"Format:":[512],"Hatem":[513],"H":[514],"Soliman,":[515],"Susan":[516],"E":[517],"Minton,":[518],"Roohi":[519],"Ismail-Khan,":[520],"Hyo":[521],"S":[522],"Han,":[523],"Nicholas":[524],"N":[525],"Vahanian,":[526],"Charles":[527],"J":[528,537],"Link,":[529],"Gene":[530],"Kennedy,":[531],"Howard":[532],"Streicher,":[533],"Daniel":[534],"Sullivan,":[535],"Scott":[536],"Antonia.":[538],"A":[539],"[abstract].":[554],"In:":[555],"Proceedings":[556],"Thirty-Seventh":[559],"Annual":[560],"CTRC-AACR":[561],"San":[562,570],"Antonio":[563],"Breast":[564],"Cancer":[565,576],"Symposium:":[566],"2014":[567],"Dec":[568],"9-13;":[569],"Antonio,":[571],"TX.":[572],"Philadelphia":[573],"(PA):":[574],"AACR;":[575],"Res":[577],"2015;75(9":[578],"Suppl):Abstract":[579],"nr":[580],"P2-15-04.":[581]},"counts_by_year":[{"year":2019,"cited_by_count":1},{"year":2016,"cited_by_count":3}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2016-06-24T00:00:00"}